Morgans names the best ASX 200 shares to buy in November

Morgans thinks that very strong returns could be on offer with these top ASX 200 shares.

| More on:
A smiling woman holds a Facebook like sign above her head.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Once a month, the team at Morgans picks out its best ASX share ideas.

These are the ASX shares that the broker thinks offer the highest risk-adjusted returns over a 12-month timeframe. They are also supported by a higher-than-average level of confidence.

Among its best ideas for the month of November are the two ASX 200 shares listed below. Here's what the broker is saying about them:

CSL Limited (ASX: CSL)

Morgans continues to rate this biotherapeutics giant as one of its best ideas. Especially after recent weakness means that CSL's shares are trading at a huge discount to historical levels. The broker appears to believe this could make now one of the best buying opportunities in a long time. It said:

While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.

Morgans has an add rating and a $328.20 price target on the company's shares.

ResMed Inc (ASX: RMD)

Another beaten-down ASX 200 share that the broker has on its best ideas list is ResMed. It believes the sleep treatment company is well-positioned for long-term growth despite the emergence of weight loss drugs like Ozempic. In light of this, it sees recent weakness as a buying opportunity. Morgans said:

While weight loss drugs have grabbed headlines and investor attention, we see these products having little impact on the large, underserved sleep disorder breathing market, and do not view them as category killers. Although quarters are likely to remain volatile, nothing changes our view that the company remains well placed and uniquely positioned as it builds a patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.

The broker has an add rating and a $32.74 price target on ResMed's shares.

Motley Fool contributor James Mickleboro has positions in CSL and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Woman checking out new iPads.
Consumer Staples & Discretionary Shares

Macquarie reveals top ASX stock picks in the consumer sectors

The top broker has revealed its favourite shares in the consumer discretionary and consumer staples sectors.

Read more »

Image from either construction, mining or the oil industry of a friendly worker.
Resources Shares

Broker names 10 ASX mining stocks set to outperform following Macquarie Conference

Twenty-two ASX mining companies presented at the annual Macquarie Conference last week.

Read more »

A man looking at his laptop and thinking.
Broker Notes

Are Super Retail Group shares a buy, hold, or sell according to Macquarie?

Let's see what the broker is saying about this popular retail stock.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Broker Notes

What does Macquarie think Steadfast shares are worth?

Could big returns be on offer from this blue chip? Let's find out.

Read more »

Broker looking at the share price.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A man in a blue collared shirt sits at his desk doing a single fist pump as he watches the Appen share price rise on his laptop
Broker Notes

These ASX 200 stocks could rise 30% to 40%

Analysts are tipping these shares to go to the moon. Let's find out why.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »